MANCHESTER, NH--(Marketwired - Nov 21, 2014) -  Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown® to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion.

In connection with this development, Boston Therapeutics received a purchase order from Sugardown Company Ltd. for 60,000 units to be tentatively shipped by the end of the first quarter of 2015.

Under the terms of the original agreement, SugarDown Company Ltd. can market sugardown® in China, Hong Kong and Macau. The new agreement expands the marketing initiative to Korea, Taiwan, Singapore, Thailand, Malaysia, Vietnam, Philippines, Myanmar, Indonesia, Laos, Brunei and Cambodia. Advance has already been granted marketing approval in Singapore, Macau, and Korea along with Hong Kong. The main China registration will enter the clinical testing phase early in 2015 with a projected approval tentatively set for later in the year. 

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "As a result of this major expansion of our marketing approval efforts across Asia, we expect to attract a substantial number of new potential sugardown® consumers. According to the International Diabetes Federation, there are 382 million people worldwide living with elevated blood sugar and that number is projected to increase to 592 million by 2035. Concerns about blood sugar levels exist in every country worldwide, and we are confident the benefits of our product will resonate with the populations of these Asian nations where carbohydrate and sugar components have been and continue to be a major impact on future national healthcare. We are pleased to expand our agreement and our clinical development with Advance Pharmaceutical and Sugardown Company, and we look forward to expanding our sugardown® distribution and, potentially, our revenues from sugardown®, in 2015."

About sugardown®

Boston Therapeutics' marketing plan for sugardown® is to out-license marketing rights to strategic partners in their jurisdictions of expertise. The Company entered into an agreement with Advance Pharmaceutical Co. Ltd. (APC), our Hong Kong-based strategic partner to develop markets for sugardown® in Hong Kong, China and Macau. This year to date, the Company has sold more than 20,000 bottles of sugardown® to APC to test the Asian market. As part of the plan to increase sales, the Company entered into a strategic marketing collaboration with Benchworks SD, LLC, a leading branding and marketing agency, aimed at driving brand awareness and growing sales of sugardown® among the large pre-diabetic population in North America. According to statistics published by the Center for Disease Control, there are 86 million people in the United States who have elevated blood glucose levels. These people may benefit by adding sugardown® to their diet and exercise regimens.

sugardown® is Boston Therapeutics' over-the-counter, natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown® is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy. The main ingredient in sugardown® is made from naturally occurring plant-based mannans (galactomannans) that when combined with a healthy lifestyle, including diet and exercise, have the ability to regulate digestive enzymes which in turn promotes healthy digestion, optimal sugar absorption and supports healthy glucose levels throughout the day. sugardown® is available in a bottle of 60 tablets or a convenient 10-tablet tube. For more information, visit sugardown® on Facebook. To order, visit

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also developed and markets sugardown®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at  

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding our distribution and sales efforts for sugardown® are subject to factors beyond our control. We can provide no assurance we or our commercial partner will be able to generate market demand for sugardown®, and thus we may not be able to generate revenue from sugardown® sales.

Moreover, we have incurred operating losses since our inception, and our ability to successfully develop, market, manufacture, distribute and sell drugs or over-the-counter products may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved. 

Contact Information:


Boston Therapeutics, Inc.
Anthony Squeglia
Chief Financial Officer
Phone: 603-935-9799